

Formulary quarterly impact report

State of Louisiana

Formulary type: Standard with ACSF

Claims Period: March 2024 - June 2024



This report contains confidential and proprietary information of CVS Health and cannot be reproduced, distributed or reprinted without permission from CVS Health. Every effort is made by CVS Caremark and its advisors to maintain the highest level of accuracy in its projections; however, because of the variability of a number of factors, which are not under the control of CVS Caremark, we cannot guarantee the estimated results shown.

Tier values of "X" indicate the drug is not part of CVS Caremark's standard formulary. Drug may be subject to PA/medical exceptions process or no drug coverage.

©2023 CVS Health and/or one of its affiliates: Confidential & Proprietary

Formulary quarterly impact report

Current utilization summary

Distinct Utilizers	Rxs	Days	Gross	Net
113,360	893,062	35,576,042	\$188,077,394	\$176,518,147

Estimated impact of formulary update

Change category	Member impact	Distinct utilizers impacted*	Percent (%) total utilizing members impacted	Impacted Rxs	Percent (%) total Rxs impacted
Exclusion	Positive	3	0.00%	8	0.00%
Exclusion	Negative	30	0.03%	49	0.01%
Exclusion	Total	33	0.03%	57	0.01%
Tier change	Positive	407	0.36%	417	0.05%
Tier change	Negative	35	0.03%	54	0.01%
Tier change	Total	442	0.39%	471	0.05%
Total		475	0.42%	528	0.06%

*The sum of distinct utilizers is greater than the Total Impacted Distinct Utilizers due to overlap among positively impacted and negatively impacted products.

Also see disclaimer notes on cover page.
©2023 CVS Health and/or one of its affiliates: Confidential & Proprietary



Formulary quarterly impact report - drug detail

Formulary impact - drug detail

State of
Louisiana OGB -
October 2024

Drug name	Therapeutic class	Change category	Member impact	Current tier	New tier	Utilizers	Rxs	Current gross cost	Current member cost	Current net cost	Alternatives	Comments	
KETOSTIX	DIAGNOSTIC TESTS	Exclusion	Negative	3	X	17	26	\$338	\$0	\$338		Exclusion is limited to restricting this NDC specifically. Member should consult prescriber on preferred options.	
TRUDHESA	MIGRAINE PRODUCTS	Exclusion	Negative	3	X	8	17	\$73,611	\$1,120	\$72,491	eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, NURTEC ODT, ONZETRA XSAIL, UBRELVY, ZEMBRACE SYMTOUCH	Triptans are the first line agents used in the treatment of migraines, in which there are multiple generic options that are covered. Additionally the CGRPs Nurtec ODT and Ubrelvy are also covered. Lastly Trudhesa has several safety concerns that the preferred agents do not have.	
KETO-DIASTIX	DIAGNOSTIC TESTS	Exclusion	Negative	3	X	5	6	\$128	\$0	\$128		Exclusion is limited to restricting this NDC specifically. Member should consult prescriber on preferred options.	
PROLENSA	OPHTHALMICS - MISC.	Tier Change	Negative	2	3	20	30	\$10,568	\$2,063	\$8,505	bromfenac, diclofenac, ketorolac, ILEVRO	This drug will remain on formulary changing from a tier 2 to tier 3	
ONEXTON	ACNE PRODUCTS	Tier Change	Negative	2	3	10	15	\$10,650	\$935	\$9,715	generics, AKLIEF, EPIDUO, TWYNEO, WINLEVI	This drug will remain on formulary changing from a tier 2 to tier 3	
TREXALL	ANTIMETABOLITES	Tier Change	Negative	2	3	3	4	\$532	\$131	\$401	methotrexate, RASUVO	This drug will remain on formulary changing from a tier 2 to tier 3	
MATULANE	ANTINEOPLASTICS MISC.	Tier Change	Negative	2	3	1	4	\$21,338	\$0	\$21,338		This drug is used to treat cancer. Members should consult their prescriber	This drug will remain on formulary changing from a tier 2 to tier 3
TABLOID	ANTIMETABOLITES	Tier Change	Negative	2	3	1	1	\$15,322	\$55	\$15,267		This drug is used to treat cancer. Members should consult their prescriber	This drug will remain on formulary changing from a tier 2 to tier 3
TYVASO DPI	PROSTAGLANDIN VASODILATORS	Exclusion	Positive	X	2	3	8	\$182,897	\$640	\$182,257			
PAXLOVID	ANTIVIRAL COMBINATIONS	Tier Change	Positive	3	2	405	408	\$554,275	\$32,400	\$521,875			
TYVASO RF KT	PROSTAGLANDIN VASODILATORS	Tier Change	Positive	3	2	2	9	\$189,238	\$675	\$188,562			

Also see disclaimer notes on cover page.

©2023 CVS Health and/or one of its affiliates: Confidential Proprietary

